These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Circadian rhythm of blood pressure in patients with benign prostatic hyperplasia. Turgut F; Bayrak O; Kanbay M; Ozkara A; Uz E; Bavbek N; Kargili A; Akcay A Scand J Urol Nephrol; 2008; 42(1):47-52. PubMed ID: 17853012 [TBL] [Abstract][Full Text] [Related]
4. [The prevention and drug correction of cardiovascular changes in prostatic cancer patients]. Gembitskiĭ EV; Begunov AV Voen Med Zh; 1994 Feb; (2):35-7. PubMed ID: 7513112 [No Abstract] [Full Text] [Related]
8. Benign prostatic hyperplasia and cardiovascular risk: a prospective study among Chinese men. Wang X; Su Y; Yang C; Hu Y; Dong JY World J Urol; 2022 Jan; 40(1):177-183. PubMed ID: 34426873 [TBL] [Abstract][Full Text] [Related]
9. Re: Shinbo et al.: Resistive index as risk factor for acute urinary retention in patients with benign prostatic hyperplasia (Urology 2010;76:1440-1445). Shenoy SP; Suvarna R; Marla PK Urology; 2011 May; 77(5):1268. PubMed ID: 21539979 [No Abstract] [Full Text] [Related]
10. [Correlation of the hourly and daily clearance in prostate adenoma]. Mal'kov PS; Guseĭnov KhS Urol Nefrol (Mosk); 1979; (5):35-8. PubMed ID: 93822 [No Abstract] [Full Text] [Related]
11. [Benign prostatic hyperplasia and urolithiasis]. Krombach P; Michel MS Urologe A; 2010 Sep; 49 Suppl 1():149-53. PubMed ID: 20812042 [TBL] [Abstract][Full Text] [Related]
12. Circadian rhythms in cardiovascular disease: the crucial hours. Detry JM; Vincent M J Hum Hypertens; 1992 Dec; 6 Suppl 1():S3-8. PubMed ID: 1293306 [TBL] [Abstract][Full Text] [Related]
14. Circadian rhythms and the heart: implications for chronotherapy of cardiovascular diseases. Manfredini R; Gallerani M; Salmi R; Fersini C Clin Pharmacol Ther; 1994 Sep; 56(3):244-7. PubMed ID: 7924118 [No Abstract] [Full Text] [Related]
15. [Clinical efficacy and safety of terazosine (setegis) in patients with benign prostatic hyperplasia with concomitant cardiovascular diseases]. Trapeznikova MF; Gurevich MA; Pozdniakov KV; Tazina SIa; Bychkova NV Urologiia; 2005; (2):50-3. PubMed ID: 15989029 [TBL] [Abstract][Full Text] [Related]
16. Consequences of Circadian Disruption on Cardiometabolic Health. Reutrakul S; Knutson KL Sleep Med Clin; 2015 Dec; 10(4):455-68. PubMed ID: 26568122 [TBL] [Abstract][Full Text] [Related]
17. [Evaluation of the effectiveness of prazosin in conservative treatment of benign prostatic hypertrophy]. Górecki R; Krzeski T; Wasik J; Borówka A Pol Tyg Lek; 1992 Jun 15-29; 47(24-26):549-51. PubMed ID: 1282713 [TBL] [Abstract][Full Text] [Related]
18. [Role of circadian rhythms and cellular clock in aging-related diseases]. Panchenko AV; Gubareva EA; Anisimov VN Adv Gerontol; 2016; 29(3):417-423. PubMed ID: 28525688 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular diseases: a therapeutic perspective around the clock. Soares AC; Fonseca DA Drug Discov Today; 2020 Jun; 25(6):1086-1098. PubMed ID: 32320853 [TBL] [Abstract][Full Text] [Related]
20. Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway. Higashi Y Int J Urol; 2017 Jun; 24(6):412-424. PubMed ID: 28332240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]